Cancer Institute of NJ Adds to its Staff

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 8
Volume 4
Issue 8

NEW BRUNSWICK, NJ--Last month, The Cancer Institute of New Jersey welcomed Joseph Aisner, MD, as its new associate director of clinical science, and added four new physician/scientists to its staff.

NEW BRUNSWICK, NJ--Last month, The Cancer Institute of New Jerseywelcomed Joseph Aisner, MD, as its new associate director of clinicalscience, and added four new physician/scientists to its staff.

Dr. Aisner will also serve as chief of the Division of MedicalOncology and professor of medicine and environment and communitymedicine. He was recruited from the University of Maryland wherehe was chief of medical oncology and director of the Cancer Center.

Joseph Germino, MD, and Eric H. Rubin, MD, have joined the Instituteas assistant professors of medicine. Dr. Germino comes from YaleUniversity School of Medicine and Dr. Rubin from Dana-Farber andHarvard Medical School.

James Stephen Goydos, MD, of the University of Pittsburgh, isa new instructor of surgery, and Thomas Joseph Kearney, MD, ofthe University of Chicago, is assistant professor of surgery.

Established in 1990, The Cancer Institute of New Jersey is a partnershipof four New Jersey hospitals and medical centers, the Universityof Medicine and Dentistry of New Jersey (UMDNJ), and the UMDNJ-RobertWood Johnson Medical School.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content